Lansoprazole in severe gastro-oesophageal reflux disease [GERD]

ABSTRACT

Lansoprazole is a new proton pump inhibitor which produces prolonged decrease of gastric acidity. It has been used in severe gastro-oesophageal reflux disease with beneficial effect. We confirmed the efficacy of Lansoprazole in severe [grade IV] reflux esophagitis at the dosage of 30mg daily for 3 months. All patients had symptomatic response after 2 to 6 weeks of therapy. Endoscopically 90% of patients had complete healing of reflux esophagitis at 12 weeks. This indicates that at conventional dosage of 30 mg daily Lansoprazole gives good symptomatic and endoscopic response in patients with gastro-oesophageal reflux disease who failed to improve with H2 receptor antagonists